Johnson & Johnson (JNJ)
148.53
-1.03
(-0.69%)
USD |
NYSE |
Apr 24, 16:00
148.21
-0.32
(-0.22%)
Pre-Market: 04:56
Johnson & Johnson Enterprise Value: 364.33B for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 364.33B |
| April 23, 2024 | 366.81B |
| April 22, 2024 | 365.75B |
| April 19, 2024 | 362.84B |
| April 18, 2024 | 357.61B |
| April 17, 2024 | 355.27B |
| April 16, 2024 | 354.50B |
| April 15, 2024 | 362.06B |
| April 12, 2024 | 361.90B |
| April 11, 2024 | 364.96B |
| April 10, 2024 | 368.35B |
| April 09, 2024 | 373.39B |
| April 08, 2024 | 371.70B |
| April 05, 2024 | 373.63B |
| April 04, 2024 | 373.90B |
| April 03, 2024 | 378.14B |
| April 02, 2024 | 386.50B |
| April 01, 2024 | 386.62B |
| March 31, 2024 | 387.61B |
| March 28, 2024 | 387.61B |
| March 27, 2024 | 387.05B |
| March 26, 2024 | 381.78B |
| March 25, 2024 | 380.45B |
| March 22, 2024 | 380.48B |
| March 21, 2024 | 381.73B |
| Date | Value |
|---|---|
| March 20, 2024 | 381.75B |
| March 19, 2024 | 382.84B |
| March 18, 2024 | 384.16B |
| March 15, 2024 | 387.58B |
| March 14, 2024 | 390.07B |
| March 13, 2024 | 394.62B |
| March 12, 2024 | 398.57B |
| March 11, 2024 | 394.93B |
| March 08, 2024 | 390.81B |
| March 07, 2024 | 389.25B |
| March 06, 2024 | 390.38B |
| March 05, 2024 | 391.90B |
| March 04, 2024 | 391.58B |
| March 01, 2024 | 397.08B |
| February 29, 2024 | 395.30B |
| February 28, 2024 | 395.71B |
| February 27, 2024 | 394.33B |
| February 26, 2024 | 393.71B |
| February 23, 2024 | 396.24B |
| February 22, 2024 | 392.89B |
| February 21, 2024 | 388.63B |
| February 20, 2024 | 386.65B |
| February 16, 2024 | 383.50B |
| February 15, 2024 | 386.80B |
| February 14, 2024 | 381.55B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
417.51B
Average
421.83B
Median
Enterprise Value Benchmarks
| Amgen Inc | 199.98B |
| Gilead Sciences Inc | 101.21B |
| Eli Lilly and Co | 718.54B |
| Merck & Co Inc | 349.66B |
| Shockwave Medical Inc | 12.04B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 5.354B |
| Revenue (Quarterly) | 21.38B |
| Total Expenses (Quarterly) | 15.31B |
| EPS Diluted (Quarterly) | 2.20 |
| Gross Profit Margin (Quarterly) | 69.55% |
| Profit Margin (Quarterly) | 25.04% |
| Earnings Yield | 9.65% |
| Operating Earnings Yield | 6.20% |
| Normalized Earnings Yield | 5.510 |